T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.45B |
| 2 |
Pinterest
PINS
|
+$1.89B |
| 3 |
T-Mobile US
TMUS
|
+$1.89B |
| 4 |
Zoom
ZM
|
+$1.77B |
| 5 |
UiPath
PATH
|
+$1.71B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$3.66B |
| 2 |
Caterpillar
CAT
|
+$1.32B |
| 3 |
Netflix
NFLX
|
+$1.18B |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$1.15B |
| 5 |
Micron Technology
MU
|
+$1.07B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.62% |
| 2 | Healthcare | 16.07% |
| 3 | Consumer Discretionary | 15.29% |
| 4 | Communication Services | 13.46% |
| 5 | Financials | 12.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SFIX
1426
Stitch Fix
SFIX
$487M
| $9.1M | ﹤0.01% |
150,836
+28,300
| +23% | +$1.45M |
|
|
PRAH
1427
DELISTED
PRA Health Sciences, Inc.
PRAH
| $9.07M | ﹤0.01% |
54,904
-3,478,717
| -98% | -$581M |
|
1428
Cloudflare
NET
$118B
| $8.83M | ﹤0.01% |
83,396
-112,039
| -57% | -$9.27M |
|
1429
Nektar Therapeutics
NKTR
$2.57B
| $8.82M | ﹤0.01% |
34,264
-1,214
| -3% | -$336K |
|
1430
Bentley Systems
BSY
$10.8B
| $8.69M | ﹤0.01% |
134,194
-1,250,654
| -90% | -$68.8M |
|
1431
Zscaler
ZS
$30.4B
| $8.61M | ﹤0.01% |
39,868
+2,735
| +7% | +$520K |
|
|
NGM
1432
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $8.56M | ﹤0.01% |
433,858
+54,395
| +14% | +$1.27M |
|
1433
Arch Capital
ACGL
$33.2B
| $8.36M | ﹤0.01% |
214,692
-8,736
| -4% | -$346K |
|
1434
Oscar Health
OSCR
$9.5B
| $8.34M | ﹤0.01% |
388,031
-113,632
| -23% | -$2.72M |
|
1435
iShares Russell 1000 Growth ETF
IWF
$129B
| $8.29M | ﹤0.01% |
122,068
-278,812
| -70% | -$18M |
|
1436
Orchestra BioMed
OBIO
$266M
| $8.26M | ﹤0.01% |
810,138
-39,862
| -5% | -$412K |
|
|
OHPAU
1437
DELISTED
Orion Acquisition Corp. Unit
OHPAU
| $8.25M | ﹤0.01% |
831,549
-41,385
| -5% | -$413K |
|
1438
ZTO Express
ZTO
$17.6B
| $8.19M | ﹤0.01% |
269,851
+190,899
| +242% | +$5.9M |
|
|
FRONU
1439
DELISTED
Frontier Acquisition Corp. Units
FRONU
| $8.15M | ﹤0.01% |
814,927
-38,438
| -5% | -$387K |
|
1440
VICI Properties
VICI
$29B
| $8.11M | ﹤0.01% |
261,327
+13,774
| +6% | +$427K |
|
1441
Berkshire Hathaway Class A
BRK.A
$1.09T
| $7.95M | ﹤0.01% |
19
| – | – |
|
1442
Warner Bros
WBD
$69.6B
| $7.88M | ﹤0.01% |
256,841
+1,206
| +0.5% | +$41.8K |
|
1443
Aramark
ARMK
$16.1B
| $7.83M | ﹤0.01% |
291,193
-43,045
| -13% | -$1.18M |
|
1444
MoonLake Immunotherapeutics
MLTX
$1.47B
| $7.81M | ﹤0.01% |
756,303
-35,982
| -5% | -$365K |
|
|
BLSA
1445
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $7.77M | ﹤0.01% |
738,045
-36,091
| -5% | -$374K |
|
1446
Wolfspeed
WOLF
$1.64B
| $7.68M | ﹤0.01% |
78,383
-627
| -0.8% | -$63.2K |
|
1447
Sprott Physical Gold and Silver Trust
CEF
$8.32B
| $7.59M | ﹤0.01% |
406,262
-284,916
| -41% | -$5.43M |
|
1448
Precision BioSciences
DTIL
$201M
| $7.47M | ﹤0.01% |
19,900
-1,056
| -5% | -$317K |
|
|
EUCRU
1449
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
| $7.45M | ﹤0.01% |
730,864
-56,026
| -7% | -$562K |
|
1450
Madrigal Pharmaceuticals
MDGL
$12.4B
| $7.43M | ﹤0.01% |
76,255
-9,286
| -11% | -$1.1M |
|
Similar funds
T. Rowe Price Associates's Q2 2021 Portfolio in Review
As of Q2 2021, T. Rowe Price Associates held 3,000 positions worth $1.08T, up 8% from $999B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2021 filing shows 159 new, 1,164 increased, 1,499 reduced and 84 closed positions. Its largest new stake was UiPath: 23,377,090 shares worth $1.52B. The largest sale was Alibaba, an estimated $3.66B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2021 buy was UiPath: 23,377,090 shares worth $1.52B.
- T. Rowe Price Associates added most to Microsoft in Q2 2021, an estimated $3.45B increase.
- T. Rowe Price Associates's biggest Q2 2021 reduction was Alibaba, cutting an estimated $3.66B.
- T. Rowe Price Associates fully exited Pershing Square Tontine Holdings, Ltd. in Q2 2021, selling an estimated $145M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $1.08T portfolio in Q2 2021.
- T. Rowe Price Associates opened 159 new positions and closed 84 in Q2 2021.
- T. Rowe Price Associates's portfolio value rose 8% quarter-over-quarter to $1.08T.
Based on T. Rowe Price Associates's 13F filing for Q2 2021, filed 16 Aug 2021.